Deals
Valeant Said to Weigh Sale of Skin, Cancer Drugs to Cut Debt
- Assets for sale could include drugs acquired from Marathon
- Sale of all products could fetch about $1 billion in total
Valeant Said to Weigh Sale of Skin, Cancer Drugs
This article is for subscribers only.
Valeant Pharmaceuticals International Inc. is exploring the sale of some of its smaller cosmetic and pharmaceutical assets, according to people familiar with the matter, as the Canadian drugmaker scrambles to raise cash and reduce debt.
The company is considering the disposal of Obagi Medical Products Inc., a dermatology company it acquired in 2013, as well as Provenge, a treatment for advanced prostate cancer that was purchased last year, said the people, who asked not to be identified because the matter is private.